» Articles » PMID: 30613828

The Neuropeptides of Ocular Immune Privilege, α-MSH and NPY, Suppress Phagosome Maturation in Macrophages

Overview
Journal Immunohorizons
Date 2019 Jan 8
PMID 30613828
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The ocular microenvironment has evolutionarily adapted several mechanisms of immunosuppression to minimize the induction of inflammation. Neuropeptides produced by the retinal pigment epithelial cells regulate macrophage activity. Two neuropeptides, α-melanocyte-stimulating hormone (α -MSH) and neuropeptide Y (NPY), are constitutively expressed by the retinal pigment epithelial cells. Together these two neuropeptides induce anti-inflammatory cytokine production in endotoxin-stimulated macrophages and suppress phagocytosis of unopsonized bioparticles. These neuropeptides do not suppress the phagocytosis of opsonized bioparticles; however, they do suppress phagolysosome activation or formation. In this report, we studied the possibility that α-MSH with NPY suppress phagosome maturation within macrophages using opsonized OVA-coated magnetic beads to isolate and analyze the phagosomes. The magnetic bead-containing intercellular vesicles were isolated and assayed for Rab5, Rab7, LAMP1, Ia, and OVA. The macrophages cotreated with α-MSH and NPY were suppressed in Rab7 recruitment to the phagosome with suppression in LAMP1 expression but not in Ia expression. The results demonstrated that the α-MSH/NPY cotreatment suppressed phagosome maturation. In addition, the a-MSH/NPY-cotreated macrophages were suppressed in their ability to Ag stimulate CD4 T cell proliferation. These results imply a potential mechanism of ocular immune privilege to divert Ag processing to prevent autoreactive effector T cells from binding their target cognate Ag within the ocular microenvironment.

Citing Articles

Loss of Pigment Epithelium Derived Factor Sensitizes C57BL/6J Mice to Light-Induced Retinal Damage.

Shelton D, Papania J, Getz T, Sellers J, Giradot P, Chrenek M bioRxiv. 2024; .

PMID: 39679905 PMC: 11643041. DOI: 10.1101/2024.12.04.626802.


Multidimensional immunotherapy for dry eye disease: current status and future directions.

Huang D, Li Z Front Ophthalmol (Lausanne). 2024; 4:1449283.

PMID: 39554604 PMC: 11564177. DOI: 10.3389/fopht.2024.1449283.


Myofibroblasts persist through immune privilege mechanisms to mediate oral submucous fibrosis: Uncovering the pathogenesis.

Sharma M, Shetty S, Soi S, Radhakrishnan R J Oral Biol Craniofac Res. 2024; 14(6):773-781.

PMID: 39502133 PMC: 11535754. DOI: 10.1016/j.jobcr.2024.10.008.


Immunomodulatory Role of Neuropeptides in the Cornea.

Puri S, Kenyon B, Hamrah P Biomedicines. 2022; 10(8).

PMID: 36009532 PMC: 9406019. DOI: 10.3390/biomedicines10081985.


The Role of Retinal Pigment Epithelial Cells in Regulation of Macrophages/Microglial Cells in Retinal Immunobiology.

Taylor A, Hsu S, Ng T Front Immunol. 2021; 12:724601.

PMID: 34484232 PMC: 8414138. DOI: 10.3389/fimmu.2021.724601.


References
1.
Ichiyama T, Zhao H, Catania A, Furukawa S, Lipton J . alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation. Exp Neurol. 1999; 157(2):359-65. DOI: 10.1006/exnr.1999.7064. View

2.
Ichiyama T, Sakai T, Catania A, Barsh G, Furukawa S, Lipton J . Inhibition of peripheral NF-kappaB activation by central action of alpha-melanocyte-stimulating hormone. J Neuroimmunol. 1999; 99(2):211-7. DOI: 10.1016/s0165-5728(99)00122-8. View

3.
Luger T, Kalden D, Scholzen T, Brzoska T . alpha-melanocyte-stimulating hormone as a mediator of tolerance induction. Pathobiology. 2000; 67(5-6):318-21. DOI: 10.1159/000028089. View

4.
de la Fuente M, Del Rio M, Medina S . Changes with aging in the modulation by neuropeptide Y of murine peritoneal macrophage functions. J Neuroimmunol. 2001; 116(2):156-67. DOI: 10.1016/s0165-5728(01)00297-1. View

5.
Ahmed A, Wahbi A, Nordlin K . Neuropeptides modulate a murine monocyte/macrophage cell line capacity for phagocytosis and killing of Leishmania major parasites. Immunopharmacol Immunotoxicol. 2001; 23(3):397-409. DOI: 10.1081/iph-100107339. View